Skip to main content
OpenTrials
Completed

NCT Number: NCT05827328

Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection

Exploring the optimal interval time in patients with the clinical diagnosis of lung cancer or mediastinal tumors indicated for thoracic surgeries after SARS-CoV-2 infection by comparing 30-day mortality and 30-day morbidity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thoracic Diseases Respiratory Tract Diseases Thoracic Surgery

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Anhui Chest Hospital, Shanghai, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient has fully understood the nature of this study and voluntarily agreed to participate by signing an informed consent form.
  • Participants of any gender between the ages of 18 and 85 are eligible.
  • Preoperative imaging evaluation +/- biopsies indicates that the patient has resectable lung cancer or mediastinal tumors without distant metastasis.

Exclusion criteria

  • Patients who have previously undergone lung surgery;
  • Patients previously infected with SARS-CoV-2 more than 6 months before thoracic surgery;
  • Patients who did not receive Chest computed tomography (CT) at admission or within 7 days before surgery, or whose Chest CT at admission suggests pneumonia or current infection with SARS-CoV-2 (confirmed by routine laboratory tests as positive nucleic acid in admission or on the day of surgery);
  • The elapsed time from SARS-CoV-2 diagnosis to surgery is within 4 weeks;
  • Local unresectable lesions or distant metastases are found intraoperatively.

Treatment and study plan

observation

Other

Observe the 30-day mortality and 30-day morbidity.

Primary outcomes

  1. The incidence of perioperative mortality

    Time frame: 30 days after surgery

    30-day mortality after surgery

Secondary outcomes

  1. The incidence of perioperative complications

    Time frame: 30 days after surgery

    30-day morbidity after surgery

Sponsors and collaborators

Lead sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Other

Registry information

Official study title

A Prospective Observational Study to Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Apr 25, 2023
Registry last updated
Jul 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.